Identifying schizophrenia patients who carry pathogenic genetic copy number variants using standard clinical assessment: retrospective cohort study
- 22 January 2020
- journal article
- research article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 216 (5) , 275-279
Abstract
Background: Copy number variants (CNVs) play a significant role in disease pathogenesis in a small subset of individuals with schizophrenia (~2.5%). Chromosomal microarray testing is a first-tier genetic test for many neurodevelopmental disorders. Similar testing could be useful in schizophrenia.Aims: To determine whether clinically identifiable phenotypic features could be used to successfully model schizophrenia-associated (SCZ-associated) CNV carrier status in a large schizophrenia cohort.Method: Logistic regression and receiver operating characteristic (ROC) curves tested the accuracy of readily identifiable phenotypic features in modelling SCZ-associated CNV status in a discovery data-set of 1215 individuals with psychosis. A replication analysis was undertaken in a second psychosis data-set (n = 479).Results: In the discovery cohort, specific learning disorder (OR = 8.12; 95% CI 1.16–34.88, P = 0.012), developmental delay (OR = 5.19; 95% CI 1.58–14.76, P = 0.003) and comorbid neurodevelopmental disorder (OR = 5.87; 95% CI 1.28–19.69, P = 0.009) were significant independent variables in modelling positive carrier status for a SCZ-associated CNV, with an area under the ROC (AUROC) of 74.2% (95% CI 61.9–86.4%). A model constructed from the discovery cohort including developmental delay and comorbid neurodevelopmental disorder variables resulted in an AUROC of 83% (95% CI 52.0–100.0%) for the replication cohort.Conclusions: These findings suggest that careful clinical history taking to document specific neurodevelopmental features may be informative in screening for individuals with schizophrenia who are at higher risk of carrying known SCZ-associated CNVs. Identification of genomic disorders in these individuals is likely to have clinical benefits similar to those demonstrated for other neurodevelopmental disorders.Keywords
This publication has 23 references indexed in Scilit:
- The Impact of Copy Number Deletions on General Cognitive Ability and Ventricle Size in Patients with Schizophrenia and Healthy Control SubjectsBiological Psychiatry, 2013
- Genome-Wide Association Study Implicates HLA-C*01:02 as a Risk Factor at the Major Histocompatibility Complex Locus in SchizophreniaBiological Psychiatry, 2012
- CNVs: Harbingers of a Rare Variant Revolution in Psychiatric GeneticsCell, 2012
- Copy number variants of schizophrenia susceptibility loci are associated with a spectrum of speech and developmental delays and behavior problemsGenetics in Medicine, 2011
- A Novel Microduplication in the Neurodevelopmental GeneSRGAP3That Segregates with Psychotic Illness in the Family of a COS ProbandCase Reports in Genetics, 2011
- Cognitive, Behavioural and Psychiatric Phenotype in 22q11.2 Deletion SyndromeBehavior Genetics, 2011
- Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital AnomaliesThe American Journal of Human Genetics, 2010
- Common polygenic variation contributes to risk of schizophrenia and bipolar disorderNature, 2009
- Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in SchizophreniaScience, 2008
- Development and validation of a measure of dysmorphology: Useful for autism subgroup classificationAmerican Journal of Medical Genetics Part A, 2008